Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Kent Mouw

Assistant Professor

Dana-Farber Cancer Institute

United States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Professors in United States Professors in Biostatistics Biostatistics professors in United States

Articles (19)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2024

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Collaborators (6)

Andrea Necchi

Associate Professor

Vita-Salute San Raffaele University

ITALY

View details

Claus Sorensen

Københavns Universitet

DENMARK

View details

Sophia Kamran

Massachusetts General Hospital

UNITED STATES

View details

Roger Li

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES

View details

Ashish Kamat

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Filipe Carvalho

Brigham and Women's Hospital

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Kent Mouw

Research Interests

Make your next move.

Explore related searches

Articles (19)

Integrating clinically actionable biomarkers into bladder cancer care — recommendations from the International Bladder Cancer Group

Bacillus Calmette-Guérin (BCG) and Beyond: Is Systemic Immunotherapy for BCG-Naïve Non–Muscle-Invasive Bladder Cancer Progress or Overreach?

Identification of an ERCC2 Mutation-Associated Mutational Signature of Nucleotide Excision Repair Deficiency in Targeted Panel Sequencing Data

Somatic likelihood tiering: an interpretable post-calling triage protocol for tumor-only whole-exome variant review

Circulating Tumor DNA in Urothelial Cancer: Practical Applications in Oncology Clinic

Radiation and Avelumab in Cisplatin-Ineligible Patients With Muscle-Invasive Bladder Cancer

Optimizing local control in the surgical management of bladder cancer

Impact of DNA repair deficiency on sensitivity to antibody-drug conjugate (ADC) payloads in bladder cancer

Urine Biopsy as Dynamic Biomarker to Enhance Clinical Staging of Bladder Cancer in Radical Cystectomy Candidates

Second malignancy probabilities in patients with prostate cancer treated with whole pelvis radiation therapy versus prostate only radiation therapy

PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer

Therapy for Muscle-Invasive Urothelial Carcinoma: Controversies and Dilemmas

RB1 loss overrides PARP inhibitor sensitivity driven by RNASEH2B loss in prostate cancer

Association Between Travel Distance and Use of Postoperative Radiation Therapy Among Men With Organ-Confined Prostate Cancer: Does Geography Influence Treatment Decisions?

Bladder preservation: Translating discovery for clinical impact in urothelial cancer

Genomic predictors of good outcome, recurrence, or progression in high-grade T1 non-muscle-invasive bladder cancer

Utilization of multimodality therapy with primary radical prostatectomy versus radiation therapy for Gleason 8–10 prostate cancer

A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma

ATM loss confers greater sensitivity to ATR inhibition than PARP inhibition in prostate cancer

Collaborators (6)

Andrea Necchi

Claus Sorensen

Sophia Kamran

Roger Li

Ashish Kamat

Filipe Carvalho

Make your next move.